Learn about the MDX-1106 clinical trial and proposed funding cuts for NIH/NCI in our daily newscast.
Dr. Martha Boone, an Atlanta urologist, explains the consequences of the new health care law. Because of her fears about Obamacare, Boone moved to a less-expensive office so she could avoid dropping Medicare patients or laying off an employee.
Aveo Pharmaceuticals, Inc. announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name ficlatuzumab (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.
If there's to be a train wreck, we governors would rather be spectators than conductors. But if the federal government is willing to reroute the train to a different, more productive track, we are here to help.
The current edition of Kidney Cancer News, the Association's period newsletter, is available online.
EntreMed, Inc. (Nasdaq:ENMD - News), today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor.
"To this end, we developed a high-throughput screen to identify small molecules derived from plants, microorganisms, and marine organisms to which CCRCC cells are sensitive. Screening over 8,000 compounds using this approach, we report here the identification of the microbially derived compound carminomycin I (CA) as an effective inhibitor of VHL-defective (VHL(-/-)) CCRCC cell proliferation..."
What is undoubtedly clear is that 10 years ago, as we peered into the crystal ball of targeted therapies, enormous toxicities and questionable outcomes were not what we expected.